Home › Research › Mild cognitive impairment
Growth-associated protein 43 is associated with faster functional decline among amyloid-positive individuals with objectively defined subtle cognitive decline and mild cognitive impairment
Amanda Inez Gonzalez, Lauren C. Edwards, Kelsey R. Thomas, Alexandra J. Weigand, Maria Bordyug, Einat K. Brenner, Uriel A. Urias, Katherine J. Bangen. Neuropsychology, 2025-03-01
Topic: Brain proteins, microglia and lab models
The CU- group had lower baseline GAP-43 than all Aβ+ groups, but not the other Aβ- groups. Higher GAP-43 levels were associated with faster decline across the entire sample. When moderation by group was examined, higher GAP-43 at baseline predicted faster functional decline for the Obj-SCD+ and MCI+ groups, compared to the CU- group. Results extend prior work investigating biomarker associations in Obj-SCD to GAP-43 and show that high baseline CSF GAP-43 is associated with a faster rate of functional decline in Aβ+ individuals who are classified as Obj-SCD or MCI. Importantly, our findings further demonstrate that CSF GAP-43 is associated with early and subtle cognitive changes detectable before the onset of MCI. (PsycInfo Database Record (c) 2025 APA, all rights reserved).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Gonzalez, A. I., Edwards, L. C., Thomas, K. R., Weigand, A. J., Bordyug, M., Brenner, E. K., et al. (2025). Growth-associated protein 43 is associated with faster functional decline among amyloid-positive individuals with objectively defined subtle cognitive decline and mild cognitive impairment. Neuropsychology. https://doi.org/10.1037/neu0000981
Vancouver
Gonzalez AI, Edwards LC, Thomas KR, Weigand AJ, Bordyug M, Brenner EK, et al. Growth-associated protein 43 is associated with faster functional decline among amyloid-positive individuals with objectively defined subtle cognitive decline and mild cognitive impairment. Neuropsychology. 2025. doi:10.1037/neu0000981. PMID: 40063372.
BibTeX
@article{gonzalez2025-40063372,
author = {Gonzalez, Amanda Inez and Edwards, Lauren C. and Thomas, Kelsey R. and Weigand, Alexandra J. and Bordyug, Maria and Brenner, Einat K. and Urias, Uriel A. and Bangen, Katherine J.},
title = {{Growth-associated protein 43 is associated with faster functional decline among amyloid-positive individuals with objectively defined subtle cognitive decline and mild cognitive impairment}},
journal = {Neuropsychology},
year = {2025},
doi = {10.1037/neu0000981},
pmid = {40063372},
url = {https://doi.org/10.1037/neu0000981}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- The CU- group had lower baseline GAP-43 than all Aβ+ groups, but not the other Aβ- groups.
- Higher GAP-43 levels were associated with faster decline across the entire sample.
- When moderation by group was examined, higher GAP-43 at baseline predicted faster functional decline for the Obj-SCD+ and MCI+ groups, compared to the CU- group.
- Results extend prior work investigating biomarker associations in Obj-SCD to GAP-43 and show that high baseline CSF GAP-43 is associated with a faster rate of functional decline in Aβ+ individuals who are classified as Obj-SCD or MCI.
- Importantly, our findings further demonstrate that CSF GAP-43 is associated with early and subtle cognitive changes detectable before the onset of MCI.
Why it matters
Among people who were amyloid-positive, higher baseline levels of the protein GAP-43 in cerebrospinal fluid were linked to faster functional decline in those with objectively defined subtle cognitive decline or mild cognitive impairment. This is a biomarker finding about predicting decline, not a treatment or cure.
Study details
- Evidence strengthLow
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neuropsychology) |
| Journal's citation record | 2 / 4 | Neuropsychology: journal h-index 183 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 3 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Katherine J. Bangen: h-index 44 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of California San Diego: institution h-index 1,852 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40063372) |
| Free to read | 2 / 2 | Free to read |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related studies in Mild cognitive impairment
Also tagged “precursor”
1,339 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,339 tagged studies.